Tokyo, Aug. 17 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062590) titled 'A study of the effectiveness and side effects of first-line amivantamab plus lazertinib combination therapy for advanced or recurrent EGFR-mutated non-small cell lung cancer' on Aug. 17.
Study Type:
Observational
Primary Sponsor:
Institute - Department of Pulmonary Medicine
Condition:
Condition - Advanced or recurrent EGFR-mutated non-small cell lung cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - This multicenter prospective observational study aims to evaluate the real-world effectiveness and safety of first-line amivantamab plus lazertinib combinatio...